Last updated: February 27, 2026
What is the drug and its current market status?
NDC 60687-0709 corresponds to Tirzepatide, marketed under the brand name Mounjaro by Eli Lilly. It is a GLP-1 receptor and GIP receptor agonist approved by the FDA in May 2022 for the treatment of Type 2 Diabetes. The drug also has potential for weight management indications.
Market overview
Indication and target population
- Approved for Type 2 Diabetes.
- Off-label uses include obesity and weight management, pending further regulatory approvals.
- Total relevant patient pool in the U.S.: approximately 37 million with Type 2 Diabetes (CDC, 2022).
Competitive landscape
- Main competitors include Novo Nordisk’s Ozempatide (semaglutide) and Wegovy (semaglutide).
- Mounjaro’s differentiated mechanism offers potential advantages, including higher efficacy on glycemic control and weight loss, based on Phase 3 trial data.
Market size and growth trends
| Year |
Estimated U.S. prescriptions |
Growth Rate |
Comments |
| 2022 |
~250,000 |
— |
Launch year, initial uptake |
| 2023 |
1 million+ |
300% |
Rapid adoption observed |
| 2024 |
2.5-3 million |
150%+ |
Increased prescriber acceptance |
| 2025 |
4-5 million |
50-60% |
Expected saturation |
Globally, demand is rising, especially in Europe and Asia-Pacific, driven by diabetes prevalence and obesity rates.
Pricing analysis
Current pricing in the U.S.
- Average wholesale price (AWP): approximately $1,017 per month, per patient (GoodRx, 2023).
- Actual payer prices: lower, due to discounts, rebates, and managed care negotiations. Estimated net price: ~$800-900/month.
Price comparison with competitors
| Drug |
Indication |
Wholesale Price |
Approval Date |
| Tirzepatide (Mounjaro) |
Diabetes, weight management |
~$1,017/month |
2022 |
| Semaglutide (Ozempic) |
Diabetes |
~$800/month |
2017 |
| Semaglutide (Wegovy) |
Obesity |
~$1,350/month |
2021 |
Note: Wegovy’s higher price reflects its obesity indication and different dosing regimens.
Price elasticity and reimbursement trends
- Demand is price-sensitive; Medicaid and Medicare coverage expands influence pricing strategies.
- Payer negotiations and rebates substantially impact net prices.
Market penetration and revenue projections
Short-term (2022-2023)
- Prescribers: Early adopters, primarily endocrinologists.
- Revenue: Estimated revenue of $2.4 billion in 2023, assuming 2 million prescriptions and an average net price of $900/month.
Medium-term (2024-2025)
- Broader adoption in primary care and obesity markets.
- Revenue could grow to $4-6 billion, driven by increased prescriptions and expanded indications.
Long-term (2026+)
- Potential for combination therapies.
- Entry into international markets with price adjustments based on regional healthcare policies.
- Total market share estimate: 15-20% of GLP-1 receptor agonist class.
Regulatory and policy factors influencing pricing
- Patent exclusivity until 2032-2034.
- Pending FDA approval for obesity in 2024 could alter pricing and marketing.
- Coverage expansions under Medicare and Medicaid programs can reduce net prices but enlarge patient access.
Risks and uncertainties
- Competitive pressure from Novo Nordisk and emerging biosimilars.
- Changes in healthcare reimbursement policies.
- Potential patent challenges or patent extensions.
Key takeaways
- Tirzepatide (NDC 60687-0709) has rapidly gained market share within the diabetes treatment segment.
- Current average wholesale price in the U.S. is around $1,017/month, with net prices lower due to rebates.
- Revenue projections reach approximately $2.4 billion in 2023, escalating to $4-6 billion by 2025.
- Competition with semaglutide variants influences pricing strategies.
- Broader indication approvals and international expansion present upside potential.
FAQs
What factors could influence Tirzepatide’s future price?
Pricing sensitivity to payer negotiations, market competition, regulatory approvals, and regional healthcare policies.
How does Tirzepatide compare with semaglutide in efficacy?
Clinical trials suggest Tirzepatide may provide superior glycemic control and weight loss outcomes.
What is the patent status, and when could generics enter the market?
Patents extend until 2032-2034; biosimilar entry depends on patent litigation outcomes but is unlikely before 2035.
What is the potential impact of expanding FDA indications?
Approval for obesity could significantly increase demand and justify higher pricing tiers.
How will international markets affect overall revenue?
Entry into Europe and Asia-Pacific can diversify revenue but may require regional price adjustments due to healthcare system differences.
References
- Centers for Disease Control and Prevention (CDC). (2022). National Diabetes Statistics Report.
- GoodRx. (2023). Mounjaro price and discounts.
- IQVIA. (2023). Pharmaceutical Market Reports.
- U.S. Food and Drug Administration (FDA). (2022). Mounjaro Approval Correspondence.
[Note: All data are estimates based on publicly available information and projections; actual prices and market performance may vary.]
